Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids.

Autor: Vidal-Torres A; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Fernández-Pastor B; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., García M; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Ayet E; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Cabot A; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Burgueño J; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Monroy X; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Aubel B; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Codony X; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Romero L; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Pascual R; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Serafini MT; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Encina G; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Almansa C; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Zamanillo D; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Merlos M; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain., Vela JM; WeLab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain.

Publikováno v: Acta pharmaceutica Sinica. B [Acta Pharm Sin B] 2023 Jan; Vol. 13 (1), pp. 82-99. Date of Electronic Publication: 2022 Sep 25.

Preliminary in vitro assessment of pharmacokinetic drug-drug interactions of EST64401 and EST64514, two sigma-1 receptor antagonists.

Autor: Reinoso RF; Early ADME, Drug Discovery and Preclinical Development, ESTEVE Pharmaceuticals, Barcelona, Spain., Yeste S; Early ADME, Drug Discovery and Preclinical Development, ESTEVE Pharmaceuticals, Barcelona, Spain., Ayet E; Early ADME, Drug Discovery and Preclinical Development, ESTEVE Pharmaceuticals, Barcelona, Spain., Pretel MJ; Early ADME, Drug Discovery and Preclinical Development, ESTEVE Pharmaceuticals, Barcelona, Spain., Balada A; Early ADME, Drug Discovery and Preclinical Development, ESTEVE Pharmaceuticals, Barcelona, Spain., Serafini MT; Early ADME, Drug Discovery and Preclinical Development, ESTEVE Pharmaceuticals, Barcelona, Spain.

Publikováno v: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2021 Apr; Vol. 51 (4), pp. 373-386. Date of Electronic Publication: 2021 Jan 20.

4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ 1 Receptor Antagonists for the Treatment of Pain.

Autor: García M; Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain., Virgili M; Carrer Baldiri Reixac, Enantia, SL, 10 Parc Científic de Barcelona, 08028 Barcelona, Spain., Alonso M; Carrer Baldiri Reixac, Enantia, SL, 10 Parc Científic de Barcelona, 08028 Barcelona, Spain., Alegret C; Carrer Baldiri Reixac, Enantia, SL, 10 Parc Científic de Barcelona, 08028 Barcelona, Spain., Fernández B; Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain., Port A; Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain., Pascual R; Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain., Monroy X; Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain., Vidal-Torres A; Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain., Serafini MT; Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain., Vela JM; Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain., Almansa C; Drug Discovery and Preclinical Development, Carrer Baldiri Reixac, ESTEVE Pharmaceuticals SA, 4-8 Parc Científic de Barcelona, 08028 Barcelona, Spain.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2020 Mar 12; Vol. 63 (5), pp. 2434-2454. Date of Electronic Publication: 2019 Dec 05.

Automated high-performance liquid chromatographic assay for lesopitron, a novel anxiolytic, in human plasma using on-line solid-phase extraction

Autor: G. Garcı́a-Encina, L. Martı́nez, R. Farrán, Serafini Mt, S. Puig

Publikováno v: Journal of Chromatography B: Biomedical Sciences and Applications. 670:103-110

A totally automated liquid chromatographic assay method based on a Prospekt solid-phase extraction unit was developed for the analysis of lesopitron and its metabolite 5-hydroxylesopitron in human plasma. On-line solid-phase extraction of lesopitron,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::909e671775faf2cffbd8b1ebd8eba41d
https://doi.org/10.1016/0378-4347(95)00138-9

ANATOMY OF SEGMENTAL DUPLICATION IN THE HUMAN BASILAR ARTERY - POSSIBLE SITE OF ANEURYSM FORMATION

Autor: DE CARO, Raffaele, Serafini, Mt, Galli, Sergio, Parenti, ANNA ROSITA, Guidolin, Diego, Munari, Pf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3657::68de121a332cd45c4828ca7020992d8f
http://hdl.handle.net/11577/2475014